Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Toripalimab Maintenance in Advanced Soft Tissue Sarcoma (Phase II)
ChiCTR2100054901Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and toripalimab in soft tissue sarcoma (STS), sponsored by West China Hospital of Sichuan University. Primary endpoint: 24-week progression-free survival rate. Started May 2021; status: recruiting.
02
Drugs
anlotinibtoripalimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2100054901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054901.